Johnathan Grant, DO
Pulmonary Disease · Vincennes, INNPI 1740272251
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 50.4% of the total. 2025 is the largest year on record at $6,889, more than ten times the $463 reported in 2019.
Across 337 payments — averaging $33.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Actelion Pharmaceuticals US, Inc.$993
- AstraZeneca$911
- GSK$565
- Boehringer Ingelheim$464
- Amgen$362
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,59614%
- Food & beverage$5,27247%
- Education$4,27938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $5,613 |
| Actelion Pharmaceuticals US, Inc. | 43 | $993 |
| AstraZeneca | 20 | $911 |
| GSK | 69 | $565 |
| Boehringer Ingelheim | 33 | $464 |
| Amgen | 24 | $362 |
| Mylan Specialty L.p. | 19 | $291 |
| Sanofi | 15 | $247 |
| Regeneron Healthcare Solutions, Inc. | 10 | $212 |
| United Therapeutics Corporation | 7 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $139 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $132 |
| Merck | 8 | $119 |
| Sunovion Pharmaceuticals Inc. | 9 | $108 |
| Grifols USA, LLC | 8 | $103 |
| Bayer | 5 | $92 |
| Insmed, Inc. | 5 | $81 |
| Verona Pharma, Inc. | 4 | $68 |
| Philips North America LLC | 4 | $62 |
| Novartis | 3 | $55 |
| Novo Nordisk | 3 | $54 |
| Baxter Healthcare | 3 | $42 |
| Genentech USA, Inc. | 1 | $38 |
| Viatris Specialty LLC | 2 | $38 |
| Pulmonx Corporation | 1 | $32 |
| Johnson & Johnson | 4 | $30 |
| Electromed, Inc. | 2 | $29 |
| Pfizer | 2 | $24 |
| Abbott | 1 | $23 |
| Resmed Corp | 1 | $17 |
| CSL Behring | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,506
- BREZTRI$145
- BRILINTA$145
- FASENRA$145
- TEZSPIRE$145
How this compares
$11,148 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 143 | $1,905,251 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 761 | $600,051 |
| OpsumitMacitentan | 29 | $366,646 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $199,893 |
| Spiriva RespimatTiotropium Bromide | 333 | $196,527 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 180 | $126,081 |
| TezspireTezepelumab-Ekko | 27 | $123,382 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 157 | $107,853 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 128 | $66,347 |
| Theophylline ErTheophylline Anhydrous | 1,099 | $62,028 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $46,240 |
| EliquisApixaban | 57 | $44,936 |
| DuleraMometasone/Formoterol | 84 | $41,120 |
| Incruse ElliptaUmeclidinium Bromide | 115 | $39,809 |
| Roflumilast | 550 | $37,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $464 | $2,240,109673 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $565 | $766,8991,173 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $993 | $366,64629 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere, Daliresp | $911 | $267,951295 claims |
| Grifols USA, LLCProlastin C | $103 | $199,89312 claims |
| PfizerEliquis | $24 | $44,93657 claims |
| MerckDulera | $119 | $41,12084 claims |
| Johnson & JohnsonXarelto | $30 | $16,82129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Vincennes
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.